Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression

Abstract

The invention relates to a combination of syrosingopine and a mitochondrial inhibitor, e.g. metformin or oligomycin, and the use of the combination of syrosingopine and a mitochondrial inhibitor for the treatment of cancer and for achieving immunosuppression. The invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of a cancer cell.

1 - 19 . (canceled) 
     
     
         20 . A method for treatment of cancer or autoimmune disease, which comprises administering a combination of syrosingopine and a mitochondrial inhibitor, or of a pharmaceutical composition comprising syrosingopine and a mitochondrial inhibitor, in a quantity effective against said disease, to a warm-blooded animal requiring such treatment. 
     
     
         21 . The method of  claim 20  wherein the mitochondrial inhibitor is metformin. 
     
     
         22 . The method of  claim 20  wherein the mitochondrial inhibitor is oligomycin. 
     
     
         23 . The method of  claim 20  wherein the cancer is selected from the group consisting of carcinoma, sarcoma, leukemia, myeloma, lymphoma, and cancers of the nervous system. 
     
     
         24 . The method of  claim 20  for use in immunosuppressive treatment of an autoimmune disease. 
     
     
         25 . The method of  claim 20  wherein the autoimmune disease is selected from the group consisting of autoimmune diseases of the skin, nervous system, connective tissue, muscle, nervous system, blood forming system, bone and inner organs. 
     
     
         26 . The method of  claim 20  wherein the combination of syrosingopine and the mitochondrial inhibitor is part of the same pharmaceutical composition. 
     
     
         27 . The method of  claim 20  wherein the combination of syrosingopine and the mitochondrial inhibitor is in different pharmaceutical compositions.